Please login to the form below

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?


In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy Watch patient record data, uptake of biosimilars remains relatively muted, with marked inconsistencies across the major European markets. With Enbrel biosimilar Benepali about to launch across EU, we ask what’s next for RA?

http://www.researchpartnership.com/news/2016/04/ft-are-biosimilars-the-answer-to-the-rising-cost-of-...


3rd June 2016

Share

Tags